MaxCyte Inc (MXCT)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $122.87M
Last updated: Nov 17, 2026 at 11:05 AM ET
MaxCyte Inc (MXCT) Stock Forecast
Analysts expect MaxCyte (MXCT) to earn -$0.25 per share in the fiscal year ending Dec 31, 2026, on revenue of $34.60M. Of 6 analysts, 5 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 2.17, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 83% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 5 | 83.3% |
| Hold | 1 | 16.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 6
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 10.1%.
- Fiscal year ending Dec 31, 2026
- -$0.25
- EPS consensus, revenue $34.60M
- Fiscal year ending Dec 31, 2027
- -$0.23
- EPS consensus, revenue $38.08M
- Next report
- Mar 12, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.25 | -$0.25 to -$0.24 | 2 | $34.60M | $34.40M to $34.91M | 4 |
| Dec 31, 2027 | -$0.23 | -$0.28 to -$0.17 | 4 | $38.08M | $36.05M to $39.90M | 6 |
Quarterly Estimates
The EPS consensus rises from -$0.08 for the quarter ending Dec 31, 2026 to -$0.07 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.08 | -$0.09 to -$0.05 | 6 | $7.53M | $6.96M to $7.98M | 7 |
| Mar 31, 2027 | -$0.07 | -$0.07 to -$0.07 | 2 | $8.11M | $7.48M to $9.02M | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 6 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 3 |
| Fiscal year ending Dec 31, 2027 | 1 | 3 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.27.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.25 | -$0.28 | -$0.28 | -$0.28 | -$0.27 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.23 | -$0.25 | -$0.25 | -$0.25 | -$0.24 | N/A |
| Quarter ending Mar 31, 2027 | -$0.07 | -$0.07 | -$0.07 | -$0.07 | -$0.07 | N/A |
Frequently Asked Questions About MXCT
What is the MXCT stock forecast?
Consensus analyst estimates put MaxCyte's EPS at -$0.25 for the fiscal year ending Dec 31, 2026, on revenue of $34.60M. The consensus rating from 6 analysts is Buy.
How do analysts rate MXCT stock?
Of 6 analysts covering MaxCyte, 0 rate it Strong Buy, 5 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from MXCT next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.25, with estimates from -$0.25 to -$0.24 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.23, with estimates from -$0.28 to -$0.17 from 4 analysts.
What revenue do analysts expect from MaxCyte next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $34.60M, with estimates from $34.40M to $34.91M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $38.08M, with estimates from $36.05M to $39.90M.
How many analysts cover MXCT?
6 analysts rate MaxCyte stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
MXCT pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts